Based in Bloomington, MN, MGi Pharma (MGi) is an oncology-focused biopharmaceutical Company. The Company acquires, develops, and markets specialty pharmaceutical and medical products for markets of unmet needs.
The Winning Solution
MGi was seeking new therapeutic drugs in development to purchase, continue research, finalize development, and ultimately commercialize for consumer sales. The principals of Genoa Partners help MGi focus on the assets of SuperGen which resulted in a $40 million investment into SuperGen plus the acquisition of the global rights to develop and sell SuperGen’s experimental drug, Dacogen, for a type of bone marrow cancer.
Based in Dublin, CA, SuperGen is a pharmaceutical company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders.